Civil Litigation,
Health Care & Hospital Law,
Government,
Administrative/Regulatory
Jun. 7, 2014
Health care fraud remains a key focus for DOJ
The Medtronic settlement is yet another in a series of examples of the DOJ's continuing efforts to zero in on health care fraud. By Thomas P. O'Brien and John J. O'Kane IV
Thomas P. O'Brien
Partner
Paul Hastings LLP
Thomas is a litigation partner with Paul Hastings in Los Angeles. Prior to joining Paul Hastings, he served as the U.S. attorney for the Central District of California.
John J. O'Kane IV
Skiermont Derby LLPEmail: okane@skiermontderby.com
Johnny represents entity and individual clients through all phases of trial and appeal.
Last week, the U.S. Department of Justice announced that Medtronic, Inc. would pay nearly $10 million to settle a qui tam lawsuit involving allegations of health care fraud.
In the 130-page complaint, which was unsealed in connection with the settlement, the relators alleged that Medtronic violated the federal False Claims Act, 31 U.S.C. Section 3729 et seq. (the "FCA"), and various state laws by providing kickbacks through cash payments, trips, meals, gifts and entertainment to ...For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In